Prof. Andrew Scott

Prof. Andrew Scott is Director, Department of Molecular Imaging and Therapy, Austin Health; leads the Tumour Targeting Program at the Olivia Newton-John Cancer Research Institute; and Professor, University of Melbourne, La Trobe University, and Monash University. His clinical and research interests are focused on molecular imaging particularly oncology applications of PET in cancer, and developing innovative strategies for targeted therapy of cancer with monoclonal antibodies, as well as global advocacy of Nuclear Medicine. His laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies. He has published 368 peer reviewed papers and 22 book chapters, and is an inventor on 21 patents. Prof. Scott is the immediate Past-President (and current Executive Council member) of the World Federation of Nuclear Medicine and Biology, and is on the Board of many significant organisations including ANSTO, ANZSNM, ARTnet, and is Chair of the Board of Cancer Trials Australia. In 2017 he was awarded Member (AM) in the General Division of the Order of Australia, and elected a Fellow of the Australian Academy of Health and Medical Sciences. In 2019 he was elected a member of the International Society for Strategic Studies in Radiology.